Dead Cat Bounce Or Bottom? Novo Jumps On Ozempic Study As Goldman Weighs In Novo Nordisk shares jumped the most in 18 months in Copenhagen trading on Thursday after its diabetes wonder drug Ozempic beat Eli Lilly's older drug Trulicity in a real-world survey of 60,000 Medicare patients with diabe......